Simvastatin Augmentation for Patients With Early-Phase Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Placebo-Controlled Trial

Schizophrenia-spectrum disorders (SSD) are associated with increased inflammatory markers, both in brain and periphery. Augmentation with drugs that lower this pro-inflammatory status may improve clinical presentation. Simvastatin crosses the blood-brain barrier, has anti- inflammatory and neuroprot...

Descripción completa

Detalles Bibliográficos
Autores principales: Sommer, Iris E, Gangadin, Shiral S, de Witte, Lot D, Koops, Sanne, van Baal, C, Bahn, Sabine, Drexhage, Hemmo, van Haren, N E M, Veling, Wim, Bruggeman, R, Martens, Peter, Wiersma, Sybren, Veerman, Selene R T, Grootens, Koen P, van Beveren, Nico, Kahn, Rene S, Begemann, Marieke J H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Regular Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266622/
https://www.ncbi.nlm.nih.gov/pubmed/33608711
http://dx.doi.org/10.1093/schbul/sbab010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8266622/
https://www.ncbi.nlm.nih.gov/pubmed/33608711
http://dx.doi.org/10.1093/schbul/sbab010

Ejemplares similares